The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: The role of tumor mutational burden (TMB) is still debated for selecting advanced non-oncogene addicted non-small-cell lung cancer (NSCLC) patients who might benefit from immune checkpoint inhibitors (ICIs). Of note, TMB failed to predict a benefit in overall survival (OS) among such pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Galvano, A., Gristina, V., Malapelle, U., Pisapia, P., Pepe, F., Barraco, N., Castiglia, M., Perez, A., Rolfo, C., Troncone, G., Russo, A., Bazan, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111593/
https://www.ncbi.nlm.nih.gov/pubmed/33940346
http://dx.doi.org/10.1016/j.esmoop.2021.100124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111593/
https://www.ncbi.nlm.nih.gov/pubmed/33940346
http://dx.doi.org/10.1016/j.esmoop.2021.100124

Ejemplares similares